Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Alan W. Partin is active.

Publication


Featured researches published by Alan W. Partin.


Urology | 1994

Evaluation of serum prostate-specific antigen velocity after radical prostatectomy to distinguish local recurrence from distant metastases☆

Alan W. Partin; Charles R. Pound; Jay D. Pearson; J. Quentin Clemens; Patricia Landis; Jonathan I. Epstein; H. Ballentine Carter; Patrick C. Walsh

OBJECTIVE Serum prostate-specific antigen (PSA) values are most useful for prediction of disease recurrence after surgery. It is unknown whether a detectable PSA level after surgery indicates a local recurrence potentially benefiting from pelvic irradiation or distant metastases requiring hormonal treatment. METHODS We analyzed postoperative rate of change of serum PSA levels as a predictor of local versus distant disease recurrence after radical prostatectomy. Between 1982 and 1991, 1,058 men underwent radical prostatectomy for localized prostate cancer and follow-up consisted of determining serum PSA levels and digital rectal examinations. Clinical follow-up of 542 men for four or more years and 78 men for eight or more years yielded ten-year actuarial disease recurrence rates of 4 percent for local recurrence, 8 percent for distant metastases, and 23 percent for an isolated elevation of serum PSA level only. Fifty-one patients with isolated elevations of PSA levels only were followed expectantly until they were diagnosed with either local or distant metastases. RESULTS A linear mixed effects regression analysis was used to model these data. Using these models, the time to a serum PSA level of 0.5 ng/mL, the PSA level one year following surgery, pathologic stage, Gleason sum, and the rate of change of PSA (PSA velocity [PSAV]) were tested as predictors of local versus distant metastases. A combination of PSAV, pathologic stage, and Gleason grade best distinguished local from distant metastases. CONCLUSIONS These data suggest that PSAV in men with an isolated elevation of PSA levels following radical prostatectomy might aid in clinical decision making.


Urologic Clinics of North America | 1993

Serum PSA after anatomic radical prostatectomy: The Johns Hopkins experience after 10 years

Alan W. Partin; Charles R. Pound; Clemens Jq; Jonathan I. Epstein; Patrick C. Walsh


Archive | 2012

Radical Retropubic and Perineal Prostatectomy

Edward M. Schaeffer; Alan W. Partin; Herbert Lepor; Patrick C. Walsh


Biomedical Research and Clinical Practice | 2017

Risk assessment for high-grade prostate cancer using a novel cancer-specific biomarker assay derived from autoantibody signatures

Xiaoju Wang; Jason Hafron; Stephen J. Freedland; Heng Yu; Alice Juang; Doris Vuong; Sandy Kamer; Luis Carbonell; Sharat Singh; Jim Arthurs; Jeanne Ohrnberger; Amanda L Fish; Kristopher Kapphahn; Alan W. Partin


Archive | 1997

Novel methods for the prediction and early detection of prostatic adenocarcinoma

Herbert Ballentine Carter; Daniel W. Chan; Alan W. Partin; Albert A. Luderer; Grant D. Carlson; Robert P. Thiel; Jay D. Pearson


Archive | 2015

Running Foot: 18 F-DCFBC Imaging of Primary Prostate Cancer

Steven P. Rowe; Kenneth L. Gage; Sheila Faraj; Katarzyna J. Macura; Nilda Gonzalez-Roibon; Gunes Guner; Enrico Munari; Alan W. Partin; Misop Han; H. Ballentine Carter; Trinity J. Bivalacqua; Amanda Blackford; Daniel P. Holt; Robert F. Dannals; George J. Netto; Martin Lodge; Ronnie C. Mease; Martin Pomper; Steve Cho; H. Morgan; James Buchanan; Sidney Kimmel


ASCO Meeting Abstracts | 2015

Very high-risk localized prostate cancer: Outcomes following definitive radiation.

Daniel Y. Song; Amol K. Narang; S.P. Robertson; A.N. Ram; Pei He; Debasish Sundi; Harleen Singh; Alex DeWeese; Stephanie Honig; Todd R. McNutt; Ashley E. Ross; Trinity J. Bivalacqua; Edward M. Schaeffer; Alan W. Partin; Theodore L. DeWeese; Phuoc T. Tran


Archive | 2011

Basic And Translational Science ProPSA and Diagnostic Biopsy Tissue DNA Content Combination Improves Accuracy to Predict Need for Prostate Cancer Treatment Among Men Enrolled in an Active Surveillance Program

Sumit Isharwal; Danil V. Makarov; Lori J. Sokoll; Patricia Landis; Cameron Marlow; Jonathan I. Epstein; Alan W. Partin; Robert W. Veltri


Archive | 2008

Biomarkers and Risk Factors Impact of Body Mass Index on Biochemical Recurrence Rates After Radical Prostatectomy: An Analysis Utilizing Propensity Score Matching

Ahmed Magheli; Soroush Rais-Bahrami; Bruce J. Trock; Elizabeth B. Humphreys; Alan W. Partin; Misop Han; Mark L. Gonzalgo


American Journal of Hematology/ Oncology | 2007

Review and synopsis of: Radical prostatectomy for clinical stage T3a disease

Stephen J. Freedland; Alan W. Partin; Elizabeth B. Humphreys; Leslie A. Mangold; Patrick C. Walsh

Collaboration


Dive into the Alan W. Partin's collaboration.

Top Co-Authors

Avatar

Jonathan I. Epstein

Johns Hopkins University School of Medicine

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Daniel W. Chan

University of Washington

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

H. Ballentine Carter

Johns Hopkins University School of Medicine

View shared research outputs
Top Co-Authors

Avatar

Lori J. Sokoll

University of Washington

View shared research outputs
Top Co-Authors

Avatar

Patricia Landis

Johns Hopkins University School of Medicine

View shared research outputs
Researchain Logo
Decentralizing Knowledge